SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Bastepe M, Juppner H, Thakker RV 2003 Parathyroid disorders. In: GloriuexFH, PettiforJM, JuppnerH (eds.) Pediatric Bone: Biology and Diseases. 1st ed. Academic Press, New York, NY, USA 488495.
  • 2
    Winer KK, Yanovski JA, Cutler GB 1996 Synthetic human parathyroid hormone 1–34 vs calcitriol and calcium in the treatment of hypoparathyroidism. JAMA 276: 631636.
  • 3
    Winer KK, Ko CW, Reynolds JC, Dowdy K, Keil M, Peterson D, Gerber LH, McGerney C, Cutler GB 2003 Long-term treatment of hypoparathyroidism: A randomized controlled study comparing parathyroid hormone-(1–34) versus calcitriol and calcium. J Clin Endocrinol Metab 88: 42144220.
  • 4
    Tashjian AH Jr , Gagel RF 2006 Teriparatide [human PTH (1–34)]: 2.5 years of experience on the use and safety of the drug for the treatment of osteoporosis. J Bone Miner Res 21: 354365.
  • 5
    Baron J, Winer KK, Yanovski JA, Cunningham AW, Laue L, Zimmerman D, Cutler GB 1996 Mutations in the Ca2+-sensing receptor gene cause autosomal dominant and sporadic hypoparathyroidism. Hum Mol Genet 5: 601606.
  • 6
    Zemel B, Leonard M, Kalkwarf H, Specker B, Moyer-Mileur L, Shepherd J, Cole TJ, Pan H, Kelly TL 2004 Reference data for whole body, lumbar spine and proximal femur for American children relative to age, gender and body size. J Bone Miner Res 19: S231.
  • 7
    Kalkwarf HJ, Zemel BS, Gilsanz V, Lappe JM, Horlick M, Oberfield S, Mahboubi S, Fan B, Frederick MM, Winer K, Shepherd JA 2007 The bone mineral density in childhood study: Bone mineral content and density according to age, sex, and race. J Clin Endocrinol Metab 92: 20872099.
  • 8
    Dempster DW, Parisien M, Silverberg SJ, Liang XG, Schnitzer M, Shen V, Shane E, Kimmel DB, Recker R, Lindsay R, Bilezikian JP 1999 On the mechanism of cancellous bone preservation in postmenopausal women with mild primary hyperparathyroidism. J Clin Endocrinol Metab 84: 15621566.
  • 9
    Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR 1987 Bone histomorphometry: Standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 2: 595610.
  • 10
    Glorieux F, Travers R, Taylor A, Bowen JR, Rauch F, Norman M, Parfitt AM 2000 Normative data for iliac bone histomorphometry in growing children. Bone 26: 103109.
  • 11
    Roschger P, Fratzl P, Eschberger J, Klaushofer K 1998 Validation of quantitative backscattered electron imaging for the measurement of mineral density distribution in human bone biopsies. Bone 23: 319326.
  • 12
    Roschger P, Paschalis EP, Fratzl P, Klaushofer K 2008 Bone mineralization density distribution in health and disease. Bone 42: 456466.
  • 13
    Winer KK, Yanovski JA, Sarani B, Cutler GB 1998 A randomized, cross-over trial of once-daily versus twice-daily parathyroid hormone 1–34 in treatment of hypoparathyroidism. J Clin Endocrinol Metab 83: 34803486.
  • 14
    Rauchenzauner M, Schmid A, Heinz-Erian P, Kapelari K, Falkensammer G, Griesmacher A, Finkenstedt G, Hogler W 2007 Sex- and age-specific reference curves for serum markers of bone turnover in healthy children from 2 months to 18 years. J Clin Endocrinol Metab 92: 443449.
  • 15
    Pearce SH, Williamson C, Kifor O, Bai M, Coulthard MG, Davies M, Lewis-Barned N, McCredie D, Powell H, Kendall-Taylor P, Brown EM, Thakker RV 1996 A familial syndrome of hypocalcemia with hypercalciuria due to mutations in the calcium-sensing receptor. N Engl J Med 335: 11151122.
  • 16
    Shiohara M, Shiozawa R, Kurata K, Matsuura H, Arai F, Yasuda T, Koike K 2006 Effect of parathyroid hormone administration in a patient with severe hypoparathyroidism caused by gain-of-function mutation of calcium-sensing receptor. Endocr J 53: 797802.
  • 17
    Takaichi K, Kurokawa K 1986 High Ca2+ inhibits peptide hormone-dependent cyclic AMP production specifically in thick ascending limbs of Henle. Miner Electrolyte Metab 12: 342346.
  • 18
    Hebert SC, Brown EM, Harris HW 1997 Role of the Ca2+-sensing receptor in divalent mineral ion homeostasis. J Exp Biol 200: 295302.
  • 19
    Brown EM 1991 Extracellular Ca2+ sensing, regulation of parathyroid cell function and role of Ca2+ and other ions as extracellular (first) messengers. Physiol Rev 71: 371411.
  • 20
    Kruse K, Kracht U 1986 Evaluation of serum osteocalcin as an index of altered bone metabolism. Eur J Pediatr 145: 2733.
  • 21
    Arlot M, Meunier PJ, Boivin G, Haddock L, Tamayo J, Correa-Rotter R, Jasqui S, Donley DW, Dalsky GP, Martin JS, Eriksen EF 2005 Differential effects of teriparatide and alendronate on bone remodeling in postmenopausal women assessed by histomorphometric parameters. J Bone Miner Res 20: 12441253.
  • 22
    Bonnic SL 2004 Skeletal anatomy in densitometry. In: BonnicSL (ed.) Bone Densitometry in Clinical Practice Application and Interpretation, 2nd ed. Humana Press, Clifton, NJ, USA 2967.
  • 23
    Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster J-Y, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH 2001 Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344: 14341441.
  • 24
    McKie J, Reynolds JC, Winer KK, Collins MT 2007 Comparison of Bone Mineral Density in Children and Adults with Hypoparathyroidism. Bone 40: S64.
  • 25
    Lindsay R, Zhou H, Cosman F, Nieves J, Dempster DW, Hodsman AB 2007 Effects of a one-month treatment with PTH(1–34) on bone formation on cancellous, endocortical, and periosteal surfaces of the human ilium. J Bone Miner Res 22: 495502.
  • 26
    Dempster DW, Cosman F, Kurland ES, Zhou H, Nieves J, Woelfert L, Shane E, Plavetic K, Muller R, Bilezikian J, Lindsay R 2001 Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: A paired biopsy study. J Bone Miner Res 16: 18461853.
  • 27
    Fox J, Miller MA, Recker RR, Bare SP, Smith SY, Moreau IA 2005 Treatment of postmenopausal osteoporotic women with parathyroid hormone 1–84 for 18 months increases cancellous bone formation and improves cancellous architecture: A study of iliac crest biopsies using histomorphometry and micro computed tomography. J Musculoskelet Neuronal Interact 5: 356357.
  • 28
    Fox J, Miller MA, Newman MK, Turner CH, Recker RR, Smith SY 2007 Treatment of skeletally mature ovariectomized rhesus monkeys with PTH(1–84) for 16 months increases bone formation and density and improves trabecular architecture and biomechanical properties. J Bone Miner Res 22: 260273.
  • 29
    Slovik DM, Rosenthal DI, Doppelt SH, Potts JT, Daly M Jr , Campbell JA, Neer RM 1986 Restoration of spinal bone in osteoporotic men by treatment with human parathyroid hormone (1–34) and 1,25-dihydroxyvitamin D. J Bone Miner Res 1: 377381.
  • 30
    Finkelstein JS, Klibanski A, Schaefer EH, Hornstein MA, Schiff I, Neer RM 1994 Parathyroid hormone for the prevention of bone loss induced by estrogen deficiency. N Engl J Med 331: 16181623.
  • 31
    Lindsay R, Nieves J, Formica C, Henneman E, Woelfert L, Shen V, Dempster D, Cosman F 1997 Randomized controlled study of effect of parathyroid hormone on vertebral bone mass and fracture incidence among postmenopausal women on estrogen with osteoporosis. Lancet 350: 550555.
  • 32
    Misof BM, Roschger P, Cosman F, Kurland ES, Tesch W, Messmer P, Dempster DW, Nieves J, Shane E, Fratzl P, Klaushofer K, Bilezikian J, Lindsay R 2003 Effects of intermittent parathyroid hormone administration on bone mineralization density in iliac crest biopsies from patients with osteoporosis: A paired study before and after treatment. J Clin Endocrinol Metab 88: 11501156.
  • 33
    Brommage R, Hotchkiss C, Lees C, Stancill M, Hock J, Jerome C 1999 Daily treatment with human recombinant parathyroid hormone-(1–34), LY333334, for 1 year increases bone mass in ovariectomized monkeys. J Clin Endocrinol Metab 84: 37573763.
  • 34
    Paschalis EP, Burr DB, Mendelsohn R, Hock JM, Boskey AL 2003 Bone mineral and collagen quality in humeri of ovariectomized cynomolgus monkeys given rhPTH (1–34) for 18 months. J Bone Miner Res 18: 769775.
  • 35
    Weber M, Roschger P, Fratzl-Zelman N, Schoberl T, Rauch F, Glorieux FH, Fratzl P, Klaushofer K 2006 Pamidronate does not adversely affect bone intrinsic material properties in children with osteogenesis imperfecta. Bone 39: 616622.
  • 36
    Fratzl P, Roschger P, Fratzl-Zelman N, Paschalis EP, Phipps R, Klaushofer K 2007 Evidence that treatment with risedronate in women with postmenopausal osteoporosis affects bone mineralization and bone volume. Calcif Tissue Int 81: 7380.
  • 37
    Abugassa S, Nordenstrom J, Jarhult J 1992 Bone mineral density in patients with familial hypocalciuric hypercalcaemia (FHH). Eur J Surg 158: 397402.
  • 38
    Dvorak MM, Siddiqua A, Ward DT, Carter DH, Dallas SL, Nemeth EF, Riccardi D 2004 Physiological changes in extracellular calcium concentration directly control osteoblast function in the absence of calcitropic hormones. Proc Natl Acad Sci USA 101: 51405145.
  • 39
    Vahle JL, Sato M, Long GG, Young JK, Francis PC, Engelhardt JA, Westmore MS, Ma YL, Nold JB 2002 Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1–34) for 2 years and relevance to human safety. Toxicol Pathol 30: 312321.
  • 40
    Vahle JL, Long GG, Sandusky G, Westmore M, Ma YL, Sato M 2004 Bone neoplasms in F344 rats given teriparatide [rhPTH(1–34)] are dependent on duration of treatment and dose. Toxicol Pathol 32: 426438.
  • 41
    Nnakwe NE 1995 The effect of aging on bone composition of female Fischer 344 rats. Mech Ageing Dev 85: 125131.
  • 42
    Tashjian AH, Chabner BA 2002 Commentary on clinical safety of recombinant human parathyroid hormone 1–34 in the treatment of osteoporosis in men and postmenopausal women. J Bone Miner Res 17: 11511161.
  • 43
    Sato M, Zeng GQ, Turner CH 1997 Biosynthetic human parathyroid hormone (1–34) effects on bone quality in aged ovariectomized rats. Endocrinology 138: 43304337.
  • 44
    Lim SK, Won YJ, Park DH, Shin SH, Yook JI, Lee HC, Huh KB 1999 Intermittent parathyroid hormone treatment can promote linear growth in the ovariectomized growing rat. Yonsei Med J 40: 166172.